Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)

https://www.relieftherapeutics.com

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100TM is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. *

	Start	2016-06-01 merged
	Group	Relief Therapeutics (Group)
	Industry	pharmaceutical active protein
	Industry 2	aviptadil (NN)
	Person	Selvaraju, Raghuram (Ram) (Relief Therapeutics 202010 Board Chairman)
	Person 2	Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group)

	Region	Genève (Geneva) GE
	Country	Switzerland
	Street	15 Avenue de Sécheron Fondation EIP, Bâtiment F2/F3
	City	1202 Genève GE
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Relief Therapeutics Holding AG. (1/20/21). "Press Release: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil". Geneva & Gundelfingen.

		Record changed: 2021-03-29